Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM). including acute myeloid leukaemia and myelodysplastic syndrome. Later. meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. https://parisnaturalfoodes.shop/product-category/dental-floss/